A Study to Assess the Bioequivalence of Ustekinumab by Two Different Injection Devices in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

April 14, 2021

Primary Completion Date

January 7, 2022

Study Completion Date

January 26, 2022

Conditions

Healthy

Interventions

DRUG

Ustekinumab

Ustekinumab will be administered as SC injection.

Trial Locations (3)

Celerion, Lincoln

PRA Health Sciences, Salt Lake City

Celerion, Tempe

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY